1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LMU-DOLPHIN-1, EU-20220, NCT00045461
|
|
2.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: Levosta-CBF-02/04, NCT00215007
|
|
3.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 20050113, NCT00243685
|
|
4.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: WIRB 20060042, NCT00443196
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DUMC03, DUKE UNIVERSITY MEDICAL CENTER, CLINICAL STUDY PROTOCOL, NCT00090610
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: 3401000, NCT00170690
|
|
7.
|
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 55/05, ALLG SC01, NHMRC Project Grant 331305, NCT00163722
|
|
8.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: PROGAST, NCT00180089
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVF4095g, NCT00434642
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3104000, NCT00437307
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0213, GOG-0213, NCT00565851
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KTN32313R, NCT00477282
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: MRC-NCRI-ICON6, MRC-NCRI-ICON6, EUDRACT-2007-001346-41, EU-20765, ZENECA-MRC-NCRI-ICON6, NCT00544973
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 006/028/DDI, NCT00533299
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MITO-8, EudraCT number: 2008-001755-22, NCT00657878
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: EORTC-62072, EORTC 62072, EU-20887, NCT00753688, PALETTE, GSK-VEG110727, EUDRACT-2008-001307-33
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MORAb003-004, NCT00849667
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 76
Sponsor: Other
Protocol IDs: PIP2, CSET 1443, NCT00949039
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22224, 2009-011400-33, NCT00976911
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OAS-07OVA, NCT00989131
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: AECM-0504007857, NCI-7229, 7229, NCT00182767
|
|
23.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: YALE-HIC-27640, YALE-012705, NCT00303888
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: H-22706, NCT00390182
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2006-0329, 7757, NCT00436501
|
